Kindred Capital, a London, UK-based early stage venture capital firm that practices equitable venture, closed its third fund, at £130M.
Backers included returning partners University of Chicago, British Patient Capital, Isomer, Industry Ventures, Legal & General, among others.
Kindred Fund III will invest in pre-seed and seed stage founders across Europe and Israel. They only lead or co-lead, writing $200k-$3m cheques in about 25–30 companies per fund. They don’t invest larger amounts up-front because they want to reserve significant funds for follow-on investments as their companies grow and scale. Equitable venture means that every entrepreneur the firm invests in becomes a co-owner of the fund.
Over the first two funds, Kindred worked with some visionary founders, tackling some of the most audacious technical and societal problems, from fintech to fertility, cell and gene therapy to SaaS pricing, robots to retirement communities.
The portfolio includes M3ter, Paddle, LabGenius, Cradle Bio, Scarlet Comply, Fung Money, Flagstone, Pave, Vault, Hofy, Natter, Five AI, RobCo, Dexory, Gaia, Gravity Sketch, Lottie, Farewill, Mojo, and Polywork, among others.
FinSMEs
21/04/2023